MACUGEN Drug Patent Profile
✉ Email this page to a colleague
When do Macugen patents expire, and when can generic versions of Macugen launch?
Macugen is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in MACUGEN is pegaptanib sodium. Additional details are available on the pegaptanib sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MACUGEN?
- What are the global sales for MACUGEN?
- What is Average Wholesale Price for MACUGEN?
Summary for MACUGEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 44 |
Drug Prices: | Drug price information for MACUGEN |
DailyMed Link: | MACUGEN at DailyMed |
![MACUGEN drug patent expirations Drug patent expirations by year for MACUGEN](/p/graph/s/t/MACUGEN-patent-expirations.png)
![Drug Prices for MACUGEN](/p/graph/drug-price/MACUGEN.png)
Recent Clinical Trials for MACUGEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Oslo University Hospital | Phase 4 |
Retina Vitreous Associates of Florida | N/A |
Vision Research Foundation | Phase 2 |
US Patents and Regulatory Information for MACUGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MACUGEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MACUGEN
See the table below for patents covering MACUGEN around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 0109390 | ⤷ Sign Up | |
Australia | 6261798 | ⤷ Sign Up | |
Germany | 69636656 | ⤷ Sign Up | |
Austria | 318143 | ⤷ Sign Up | |
Australia | 7282398 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MACUGEN
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0957929 | SPC024/2006 | Ireland | ⤷ Sign Up | SPC024/2006:, EXPIRES: 20210130 |
0957929 | 300234 | Netherlands | ⤷ Sign Up | 300234, 20171017, EXPIRES: 20210130 |
0957929 | SPC/GB06/021 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
0957929 | PA2006004 | Lithuania | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131 |
0957929 | 06C0021 | France | ⤷ Sign Up | PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |